Characterization of the selective in vitro and in vivo binding properties of crenezumab to oligomeric Aβ

BACKGROUND: Accumulation of amyloid β (Aβ) in the brain is proposed as a cause of Alzheimer’s disease (AD), with Aβ oligomers hypothesized to be the primary mediators of neurotoxicity. Crenezumab is a humanized immunoglobulin G4 monoclonal antibody that has been shown to bind to synthetic monomeric...

Descripción completa

Detalles Bibliográficos
Autores principales: Meilandt, William J., Maloney, Janice A., Imperio, Jose, Lalehzadeh, Guita, Earr, Tim, Crowell, Susan, Bainbridge, Travis W., Lu, Yanmei, Ernst, James A., Fuji, Reina N., Atwal, Jasvinder K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6886224/
https://www.ncbi.nlm.nih.gov/pubmed/31787113
http://dx.doi.org/10.1186/s13195-019-0553-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6886224/
https://www.ncbi.nlm.nih.gov/pubmed/31787113
http://dx.doi.org/10.1186/s13195-019-0553-5

Ejemplares similares